Payment overview · 2025
General Payments
$2,955.16
124 reported records · 24 companies
Healthcare provider profile · identity verified
Patamaporn Lekprasert, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · ELKINS PARK, PA · NPI 1255560421
Verified facts
What the public records show
CMS Open Payments records show Patamaporn Lekprasert, M.D. received $2,955.16 in general payments during 2025 across 124 reported records.
Xeris Pharmaceuticals, Inc. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus, Wegovy.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $449.42 | 15.2% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $423.19 | 14.3% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $325.89 | 11.0% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $276.56 | 9.4% | 11 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $208.89 | 7.1% | 11 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $158.54 | 5.4% | 5 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.54 | 4.8% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.98 | 4.6% | 9 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $89.67 | 3.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $88.14 | 3.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.09 | 2.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.67 | 2.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $65.56 | 2.2% | 3 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $63.51 | 2.1% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $62.05 | 2.1% | 3 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.50 | 2.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.27 | 1.5% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $39.54 | 1.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $35.99 | 1.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $28.12 | 0.9% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $27.97 | 0.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.71 | 0.9% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.97 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.39 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,950.95 | 123 |
| Education | $4.21 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $413.06 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $276.56 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $222.79 | 10 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $208.89 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $204.82 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $178.77 | 8 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $158.54 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $89.67 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $88.14 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $86.09 | 5 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $84.09 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $65.56 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $63.51 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $62.05 | 3 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $58.50 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.30 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $39.54 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $35.99 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $34.87 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.03 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $27.97 | 2 | 2025 |
Source payment records
|
|||||
| GENOTROPIN Normalized: genotropin |
Drug | PFIZER INC. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| SOMAVERT Normalized: somavert |
Drug | PFIZER INC. | $26.71 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 143 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 388 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
140 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
217 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
388 | 85 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 388 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 83 |
| Metformin Hcl | Metformin Hcl | 276 | 77 |
| Trulicity | Dulaglutide | 217 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 57 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 165 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 153 | 44 |
| Jardiance | Empagliflozin | 143 | 30 |
| Mounjaro | Tirzepatide | 140 | 25 |
| Glipizide | Glipizide | 136 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 38 |
| Farxiga | Dapagliflozin Propanediol | 101 | 21 |
| Novolog Flexpen | Insulin Aspart | 84 | 31 |
| Vascepa | Icosapent Ethyl | 78 | suppressed |
| Methimazole | Methimazole | 76 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 68 | 14 |
| Gabapentin | Gabapentin | 63 | suppressed |
| Januvia | Sitagliptin Phosphate | 55 | 12 |
| Testosterone | Testosterone | 55 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Ezetimibe | Ezetimibe | 49 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 48 | 19 |
| Metformin Hcl Er | Metformin Hcl | 45 | 12 |
| Glipizide Er | Glipizide | 43 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 15 |
| Lisinopril | Lisinopril | 43 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Glimepiride | Glimepiride | 40 | 14 |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | 12 |
| Repaglinide | Repaglinide | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 16 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,955.16 · 124 records | Xeris Pharmaceuticals, Inc. | AFREZZA, CRYSVITA, Dexcom G6 Transmitter, EVENITY, GENOTROPIN, GVOKE HYPOPEN, IMCIVREE, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MOUNJARO, Ozempic, PROLIA, QUTENZA, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, SOMAVERT, TEPEZZA, TERIPARATIDE, TWIIST, TZIELD, Tymlos, Veozah, Wegovy, Yorvipath | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error